We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.05 | -0.11% | 43.45 | 43.64 | 43.175 | 43.63 | 2,045,663 | 01:00:00 |
From May 2019 to May 2024
LONDON-- GlaxoSmithKline PLC (GSK.LN) Monday said it submitted sirukumab, a rheumatoid arthritis treatment it is developing with fellow drug company Janssen Biologics Ireland, for approval by the European Medicines Agency.
Glaxo shares at 1138 GMT, down 10 pence, or 0.7%, at 1,589 pence valuing the company at GBP77.45 billion.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
(END) Dow Jones Newswires
September 12, 2016 07:55 ET (11:55 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
